Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
Diagnosis & Disease Information
KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
Tyrer-Cuzick Breast Cancer Model Well-Calibrated Among Most Races/Ethnicities
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...